Your browser doesn't support javascript.
loading
CRISPR/Cas9 produces anti-hepatitis B virus effect in hepatoma cells and transgenic mouse.
Zhu, Wei; Xie, Kun; Xu, Yuanjian; Wang, Le; Chen, Kaiming; Zhang, Longzhen; Fang, Jianmin.
Afiliación
  • Zhu W; Laboratory of Molecular Medicine, School of Life Sciences and Technology, Tongji University, Shanghai 200092, China. Electronic address: zhuwei8247@aliyun.com.
  • Xie K; Laboratory of Molecular Medicine, School of Life Sciences and Technology, Tongji University, Shanghai 200092, China.
  • Xu Y; Laboratory of Molecular Medicine, School of Life Sciences and Technology, Tongji University, Shanghai 200092, China.
  • Wang L; Laboratory of Molecular Medicine, School of Life Sciences and Technology, Tongji University, Shanghai 200092, China.
  • Chen K; Laboratory of Molecular Medicine, School of Life Sciences and Technology, Tongji University, Shanghai 200092, China.
  • Zhang L; Laboratory of Molecular Medicine, School of Life Sciences and Technology, Tongji University, Shanghai 200092, China.
  • Fang J; Laboratory of Molecular Medicine, School of Life Sciences and Technology, Tongji University, Shanghai 200092, China. Electronic address: jfang@Tongji.edu.cn.
Virus Res ; 217: 125-32, 2016 06 02.
Article en En | MEDLINE | ID: mdl-27049051
Chronic infection of hepatitis B virus (HBV) is at risk of liver cirrhosis and hepatocellular carcinoma and remains one of the major public health problems worldwide. It is a major barrier of persistence HBV cccDNA under current antiviral therapy as novel strategies of disrupting HBV cccDNA is pressing. The (CRISPR)/Cas9 system is presently emerging in gene editing and we also apply it for targeting and deleting the conserved regions of HBV genome. Two homologous sequences of HBV S and X genes were carried with CRISPR/Cas9 endonuclease to build pCas9 constructs, which may mediate anti-HBV effects of in vitro and in vivo systems in this study. The results showed the better anti-HBV productions by pCas9-2 and without significant differences in between Huh7 and HepG2 cells. CRISPR/Cas9 direct cleavage and mutagenesis were further analyzed of in vitro system. In the M-TgHBV mouse model of HBV, injection of pCas9 constructs by hydrodynamics decreased HBsAg of sera and liver HBcAg. In conclusion, this designed CRISPR/Cas9 system can induce anti-HBV effects and potentially consider as a novel therapeutic agent against chronic HBV infection.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antivirales / Proteínas Bacterianas / Virus de la Hepatitis B / Endonucleasas / Hepatitis B Límite: Animals / Humans Idioma: En Revista: Virus Res Asunto de la revista: VIROLOGIA Año: 2016 Tipo del documento: Article Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antivirales / Proteínas Bacterianas / Virus de la Hepatitis B / Endonucleasas / Hepatitis B Límite: Animals / Humans Idioma: En Revista: Virus Res Asunto de la revista: VIROLOGIA Año: 2016 Tipo del documento: Article Pais de publicación: Países Bajos